Akebia Therapeutics share price logo

Akebia Therapeutics

NASDAQ: AKBA

$0.91

-0.01

(-0.89%)

as on

Akebia Therapeutics Stock Performance

as on August 22, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.91
    $0.95
    downward going graph

    0.13%

    Downside

    4.26%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.82
    $3.32
    downward going graph

    9.71%

    Downside

    264.35%

    Upside

    downward going graph

Akebia Therapeutics share price movements today

Previous Close
$0.92
Open
$0.92
Volume
5.7M
Market Cap
$241.9M
Day's Low - High
$0.91 - $0.95
52 Week Low - High
$0.82 - $3.32

Akebia Therapeutics Historical Returns

1 Month Return
-34.87 %
3 Month Return
-17.66 %
1 Year Return
-73.14 %
3 Year Return
-30.18 %
5 Year Return
-65.91 %

Akebia Therapeutics Stock Fundamentals & Key Indicators

Check Akebia Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$241.9M

EPS (TTM)

-0.13

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-4.3M

Revenue (TTM)

219.1M

Profit Margin

-13.54%

Return On Equity TTM

-109.38%

Akebia Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Akebia Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Akebia Therapeutics image
Akebia Therapeutics
BUY$241.9M-65.91%NA-13.54%NA
United Therapeutics image
United Therapeutics
BUY$21.4B145.28%16.5886.14%NA
Viatris image
Viatris
HOLD$18.6B9.88%-44.5634.83%2.9899999999999998%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
BUY$42.7BNA19.814.55%126.42999999999999%
Zoetis image
Zoetis
BUY$30.5B-64.28%12.4770.87%2.76%
See all

Stock Returns calculator for Akebia Therapeutics Stock including INR - Dollar returns

The Akebia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Akebia Therapeutics investment value today

Current value as on today

₹30,732

Returns

-₹69,268

(-69.27%)

Returns from Akebia Therapeutics Stock

-₹71,963 (-71.96%)

Dollar Impact

₹2,695 (+2.7%)

Analyst Recommendation on Akebia Therapeutics Stock

Based on 3 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 3 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Akebia Therapeutics. Average target price of $3.8

Akebia Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Akebia Therapeutics.

What analysts predicted

76.02%UPSIDE

Target Price

$3.8

Current Price

$0.9112

Analyzed by

3 Analysts

Target

$3.80

Akebia Therapeutics target price $3.8, a slight upside of 76.02% compared to current price of $0.9112. According to 3 analysts rating.

Indian Investors' Interest in Akebia Therapeutics Stock

Search interest for Akebia Therapeutics Stock has decreased by -11% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-11% versus previous 30 day period

Akebia Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
32
43
37
46
57
62
58
57
53
49
Gross Profit
29
35
23
26
49
52
49
45
40
38
Operating Income
-14
-8
-12
-14
13
14
4
-8
-4
-6
EBITDA
-4
1
-4
-6
14
7
6
-6
-13
-4
Interest Expense
2
2
6
6
7
6
4
4
4
3
Depreciation
9
9
9
9
0
0
0
0
0
0
Income Before Tax
-17
-8
-20
-22
6
0
1
-11
-8
-8
Income Tax Expense
9
-
-
-
-
-
0
1
0
0
Net Income
-17
-8
-20
-22
6
0
0
-12
-9
-8
Net Profit Margin
-55.16%
-19.66%
-53.54%
-49.04%
10.66%
0.40%
0.92%
-21.25%
-16.91%
-18.13%

Akebia Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
177
207
335
295
213
292
194
160
236
Gross Profit
-114
177
200
189
0
60
269
120
97
196
Operating Income
-136
-79
-178
-286
-376
-265
-80
-46
-50
23
EBITDA
-136
-76
-175
-247
-342
-227
3
-8
-13
21
Interest Expense
0
2
6
38
8
19
15
6
18
24
Depreciation
-
0
2
38
33
37
37
37
37
1
Income Before Tax
-135
-76
-171
-286
-383
-282
-94
-51
-69
-3
Income Tax Expense
0
-2
-28
-6
-33
-37
13
41
-
1
Net Income
-135
-76
-171
-279
-349
-244
-94
-51
-69
-5
Net Profit Margin
-8843.45%
-43.21%
-82.75%
-83.48%
-118.48%
-114.65%
-32.22%
-26.68%
-43.33%
-2.26%

Akebia Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-8
-20
-22
6
0
0
-12
-9
-8
Operating Cash Flow
-10
-6
-4
-13
22
28
31
-21
3
Investing Cash Flow
0
0
0
0
0
0
-7
0
-4
Financing Cash Flow
7
1
22
74
1
1
-4
0
-6
Change in Cash
-2
-5
17
61
23
29
18
-22
-7

Akebia Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-76
-143
-279
-383
-282
-92
-51
-69
-5
Operating Cash Flow
-56
-97
-257
-110
-252
-73
-23
-40
67
Investing Cash Flow
-177
36
211
-40
39
0
-
0
-7
Financing Cash Flow
116
96
88
231
133
14
-25
49
72
Change in Cash
-117
35
42
81
-79
-58
-48
8
132

Mutual Funds that own Akebia Therapeutics Stock

Check out the Mutual Funds with significant holdings in Akebia Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.930833%
10892584
Fidelity Salem Street Trust
1.023855%
2837166
Fidelity Concord Street Trust
0.954239%
2644258
VANGUARD SCOTTSDALE FUNDS
0.527028%
1460430
VANGUARD WORLD FUND
0.273537%
757990
See all

Global Institutional Holdings in Akebia Therapeutics

Funds
Holdings
Vanguard
4.91%
iShares
3.99%
Fidelity
0.65%
Schwab
0.54%
SPDR
0.31%
See all

Akebia Therapeutics News & Key Events

  • img

    Today's Timeline - 30 June

    Tue, 06:15 PM

    -

    Akebia and U.S. Renal Care report positive interim results from VOICE trial, leading to early trial halt due to safety outcomes.

Insights on Akebia Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -12.24M → -8.90M (in $), with an average increase of 18.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, United Therapeutics Corporation Common Stock has given 67.7% return, outperforming this stock by 138.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 125.4% return, outperforming this stock by 150.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, AKBA stock has moved down by -29.3%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 5 quarters, 62.47M → 49.12M (in $), with an average decrease of 5.8% per quarter

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
OrganisationAkebia Therapeutics
Headquarters245 First Street, Cambridge, MA, United States, 02142
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. John P. Butler MBA
E-voting on sharesClick here to vote

Key Management of Akebia Therapeutics

Name

Title

Mr. Nicholas Grund

Senior VP & Chief Commercial Officer

Mr. Richard C. Malabre

Senior VP & Chief Accounting Officer

Ms. Carolyn M. Rucci

Senior VP, Chief Legal Officer & Secretary

Mr. John P. Butler MBA

CEO, President & Director

Mr. Erik John Ostrowski M.B.A.

Chief Business Officer, Senior VP, CFO & Treasurer

Dr. Steven Keith Burke M.D.

Senior VP and Chief Research & Development Officer

Dr. Justin McCue Ph.D.

Senior VP & Chief Technology Officer

Mercedes Carrasco

Senior Director of Investor & Corporate Communications

Ms. Meredith Bowman

Senior VP & Chief People Officer

FAQs

What is Akebia Therapeutics share price today?

Akebia Therapeutics share price today is $0.91 as on at the close of the market. Akebia Therapeutics share today touched a day high of $0.95 and a low of $0.91.

What is the 52 week high and 52 week low for Akebia Therapeutics share?

Akebia Therapeutics share touched a 52 week high of $3.32 on and a 52 week low of $0.82 on . Akebia Therapeutics stock price today i.e. is closed at $0.91,which is 72.55% down from its 52 week high and 10.76% up from its 52 week low.

What is Akebia Therapeutics's market capitalisation today?

Akebia Therapeutics market capitalisation is $0.00T as on .

How to invest in Akebia Therapeutics Stock (AKBA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Akebia Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Akebia Therapeutics Shares that will get you 1.6462 shares as per Akebia Therapeutics share price of $0.91 per share as on August 22, 2026 at 1:29 am IST.

What is the minimum amount required to buy Akebia Therapeutics Stock (AKBA) from India?

Indian investors can start investing in Akebia Therapeutics (AKBA) shares with as little as ₹95.685 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.85 in Akebia Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Akebia Therapeutics share’s latest price of $0.91 as on August 22, 2026 at 1:29 am IST, you will get 10.9745 shares of Akebia Therapeutics. Learn more about fractional shares .

What are the returns that Akebia Therapeutics has given to Indian investors in the last 5 years?

Akebia Therapeutics stock has given -65.91% share price returns and 29.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?